Belite Bio, Inc.(纳斯达克代码:BLTE)近日宣布,其针对斯特格特病变1型(Stgd1)研发的候选药物Tinlarebant,已顺利完成名为“DRAGON II”的临床试验的患者入组工作。这项关键性研究的推进,标志着公司在治疗这种罕见眼科疾病领域取得了重要阶段性成果。
Belite Bio, Inc.(纳斯达克代码:BLTE)近日宣布,其针对斯特格特病变1型(Stgd1)研发的候选药物Tinlarebant,已顺利完成名为“DRAGON II”的临床试验的患者入组工作。这项关键性研究的推进,标志着公司在治疗这种罕见眼科疾病领域取得了重要阶段性成果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.